Phaseline

Targets › PMEL

PMEL (Melanocyte protein PMEL): drug programs, companies and trials

1 program from 1 company in 13 trials: 7 Phase 2, 3 Phase 3, 3 Phase 1; Oncology; next expected readout Mar 2028.

Forms physiological amyloids that play a central role in melanosome morphogenesis and pigmentation. The maturation of unpigmented premelanosomes from stage I to II is marked by assembly of processed amyloidogenic fragments into parallel fibrillar sheets, which elongate the vesicle into a striated ellipsoidal shape. (UniProt, P40967)

Open in Phaseline: the race on PMEL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmunocoreTebentafusp
Melanocyte protein PMEL binding agent
PMELPhase 3Advanced Melanoma; Uveal Melanoma; Melanoma (Skin); Locally Advanced Unresectable Uveal Melanoma …Mar 2028

Conditions

Uveal Melanoma (3) Metastatic Uveal Melanoma (3) Advanced Melanoma (2) Melanoma (Skin) (1) Locally Advanced Unresectable Uveal Melanoma (1) Mestastatic Uveal Melanoma (1) HLA-A*0201 Positive Cells Present (1) Uveal Melanoma, Metastatic (1)

Modalities

mixed (1)

Companies

Immunocore (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.